CA3047397A1 - Compositions and methods for inhibiting seizures - Google Patents

Compositions and methods for inhibiting seizures Download PDF

Info

Publication number
CA3047397A1
CA3047397A1 CA3047397A CA3047397A CA3047397A1 CA 3047397 A1 CA3047397 A1 CA 3047397A1 CA 3047397 A CA3047397 A CA 3047397A CA 3047397 A CA3047397 A CA 3047397A CA 3047397 A1 CA3047397 A1 CA 3047397A1
Authority
CA
Canada
Prior art keywords
composition
bacteria
subject
parabacteroides
diet
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3047397A
Other languages
English (en)
French (fr)
Inventor
Elaine Hsiao
Jessica Yano
Helen VUONG
Christine OLSON
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California San Diego UCSD
Original Assignee
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California San Diego UCSD filed Critical University of California San Diego UCSD
Publication of CA3047397A1 publication Critical patent/CA3047397A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/30—Dietetic or nutritional methods, e.g. for losing weight
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0216—Bacteriodetes, e.g. Bacteroides, Ornithobacter, Porphyromonas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K2035/11—Medicinal preparations comprising living procariotic cells
    • A61K2035/115—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Polymers & Plastics (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Dairy Products (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
CA3047397A 2016-12-20 2017-12-20 Compositions and methods for inhibiting seizures Pending CA3047397A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662436711P 2016-12-20 2016-12-20
US62/436,711 2016-12-20
US201762447992P 2017-01-19 2017-01-19
US62/447,992 2017-01-19
PCT/US2017/067548 WO2018119048A1 (en) 2016-12-20 2017-12-20 Compositions and methods for inhibiting seizures

Publications (1)

Publication Number Publication Date
CA3047397A1 true CA3047397A1 (en) 2018-06-28

Family

ID=62627881

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3047397A Pending CA3047397A1 (en) 2016-12-20 2017-12-20 Compositions and methods for inhibiting seizures

Country Status (7)

Country Link
US (3) US11129858B2 (https=)
EP (1) EP3558329B1 (https=)
JP (1) JP7166280B2 (https=)
CN (2) CN110325196B (https=)
AU (1) AU2017382197B2 (https=)
CA (1) CA3047397A1 (https=)
WO (1) WO2018119048A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017382197B2 (en) 2016-12-20 2022-12-01 The Regents Of The University Of California Compositions and methods for inhibiting seizures
PL3600363T3 (pl) 2017-06-14 2021-06-14 4D Pharma Research Limited Kompozycje zawierające szczepy bakteryjne
WO2020058979A2 (en) * 2018-09-20 2020-03-26 Yeda Research And Development Co. Ltd. Methods of treating amyotrophic lateral sclerosis
US11911419B2 (en) 2018-09-27 2024-02-27 Finch Therapeutics Holdings Llc Compositions and methods for treating epilepsy and related disorders
WO2020076043A1 (ko) * 2018-10-08 2020-04-16 한국생명공학연구원 우울증의 예방 또는 치료 효과를 가지는 장내 미생물 및 이의 용도
CN110227085A (zh) * 2019-07-16 2019-09-13 江苏省中医院 Akkermansia Muciniphila在制备抗抑郁药物或者保健品中的应用
JP7431964B2 (ja) * 2020-06-12 2024-02-15 森永乳業株式会社 ミトコンドリア機能改善用組成物
CN113367328B (zh) * 2021-06-11 2023-02-21 无锡市人民医院 一种调节肠道菌群和能量代谢的多阶段生酮饮食配方
KR20240040089A (ko) * 2021-07-20 2024-03-27 위니베르시트카솔리끄드루뱅 보상 조절 장애의 방지 및/또는 치료
WO2023001368A1 (en) * 2021-07-20 2023-01-26 Université Catholique de Louvain Prevention and/or treatment of reward dysregulation disorders

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6461607B1 (en) 1998-08-24 2002-10-08 Ganeden Biotech, Inc. Probiotic, lactic acid-producing bacteria and uses thereof
WO2014075745A1 (en) * 2012-11-19 2014-05-22 Université Catholique de Louvain Use of akkermansia for treating metabolic disorders
EP2958575B1 (en) * 2013-02-22 2019-04-03 The Regents of The University of California Composition comprising lactobaccilus johnsonii 456 and its use in treating or preventing diseases
KR101445243B1 (ko) * 2014-03-28 2014-09-29 서울대학교산학협력단 장내 세균의 군집과 기능의 변화를 이용한 대사성 및 염증성 질환의 조기진단
MA41020A (fr) * 2014-11-25 2017-10-03 Evelo Biosciences Inc Compositions probiotiques et prébiotiques, et leurs procédés d'utilisation pour la modulation du microbiome
BR112017024928A2 (pt) * 2015-05-21 2018-07-31 Yeda Research And Development Co Ltd Métodos para prevenção da diabetes ou pré- diabetes em um indivíduo, para melhoria da resposta à glicose em um indivíduo com intolerância à glicose, para manutenção da resposta à glicose em um indivíduo com tolerância à glicose e para melhoria da saúde de um indivíduo, composição probiótica e composição farmacêutica
AU2016268158B2 (en) * 2015-05-22 2022-03-17 Arizona Board Of Regents On Behalf Of Arizona State University Methods for treating autism spectrum disorder and associated symptoms
AU2017382197B2 (en) 2016-12-20 2022-12-01 The Regents Of The University Of California Compositions and methods for inhibiting seizures
WO2020191002A1 (en) 2019-03-18 2020-09-24 The Regents Of The University Of California Compositions and methods for treating cushing's disease

Also Published As

Publication number Publication date
JP2020502281A (ja) 2020-01-23
WO2018119048A1 (en) 2018-06-28
US12364717B2 (en) 2025-07-22
AU2017382197A1 (en) 2019-07-04
EP3558329C0 (en) 2024-01-31
US20220184144A1 (en) 2022-06-16
EP3558329A4 (en) 2020-07-22
CN110325196B (zh) 2024-08-27
EP3558329B1 (en) 2024-01-31
US11883441B2 (en) 2024-01-30
AU2017382197B2 (en) 2022-12-01
EP3558329A1 (en) 2019-10-30
CN119033822A (zh) 2024-11-29
US20200384037A1 (en) 2020-12-10
US11129858B2 (en) 2021-09-28
CN110325196A (zh) 2019-10-11
US20240238350A1 (en) 2024-07-18
JP7166280B2 (ja) 2022-11-07

Similar Documents

Publication Publication Date Title
US12364717B2 (en) Compositions and methods for inhibiting seizures
US12292445B2 (en) Methods of selecting subjects for treatment with metabolomic modulators
TWI812624B (zh) 包含細菌品系之組成物
JP2018513196A (ja) マイクロバイオーム制御因子及び関連するその使用
EP3965820A1 (en) Compositions and methods for promoting healthy neural development in an unborn baby
CN116096376A (zh) 精子运动性改善剂以及精子运动性改善方法
CN111263590A (zh) 具有体力提高作用及抗疲劳作用中的一种以上作用的组合物
US20220265733A1 (en) Compositions comprising bacterial strains
WO2025038777A2 (en) Probiotics and methods to reduce appetite
EP3976026A2 (en) Compositions and methods for modulating cognitive behavior
US20250025516A1 (en) Compositions and methods for inhibiting seizures
EP4003381A1 (en) Compositions and methods for treating skin infections and other diseases
Favaron et al. The ageing microbiome, pharmaceutical considerations, and therapeutic opportunities
WO2026044228A1 (en) Chorismate pathway metabolite compositions and methods of use thereof
KR20240040059A (ko) 불포화 하이드록삼산 유도체 및 암모니아 연관 질환 또는 장애의 치료 및 예방을 위한 이의 용도
JP2003238423A (ja) 血中コレステロール低下剤および血中コレステロール低下飲食品
WO2025189253A1 (en) Microbiota compositions and methods for treating disorders
US20250228909A1 (en) Therapeutic compositions and methods
NZ760637B2 (en) Compositions comprising bacterial strains
NZ760637A (en) Compositions comprising bacterial strains

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220922

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD

Year of fee payment: 7

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241213

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241213

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241213

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250210

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20250606

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250616

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250723

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250723

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 8TH ANNIV.) - STANDARD

Year of fee payment: 8

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251212

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251212

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20260407